Atara Biotherapeutics (NASDAQ:ATRA) has announced plans to cut around 50% of its workforce, just a little over a week after it said the FDA had declined to approve its immunotherapy Ebvallo.

Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara Biotherapeutics, Inc.") (NASDAQ:ATRA) concerning possible violations of federal ...

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA). Investors who purchased Atara ...

which owned a controlling interest in LOGOS. The new entity to be controlled by the management team in Singapore will focus on the development, ownership and management of logistics and industrial ...

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Creating a strong brand identity ...